Luca Nuvoli

@article{Schena2026,

title = {Association between ABO blood group and survival in patients with esophageal, gastric, and colorectal cancer: a systematic review and meta-analysis},

author = {Simone Schena and Luca Nuvoli and Stefano De Pascale and Uberto Fumagalli Romario and Annaclara Sileo and Chiara Doccioli and Elisa Di Maggio and Giuseppe Palmieri and Carlo La Vecchia and Saverio Caini and Sara Gandini},

doi = {10.1097/cej.0000000000001033},

issn = {1473-5709},

year  = {2026},

date = {2026-08-14},

publisher = {Ovid Technologies (Wolters Kluwer Health)},

abstract = {

                    

                    

                      The ABO blood group, has been investigated as a prognostic factor in esophageal, gastric and colorectal cancer, with conflicting results. We conducted a systematic review and meta-analysis to assess the effect of ABO blood type on overall survival (OS). We searched PubMed and Embase from inception to February 2026 following Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. Two reviewers independently screened studies reporting hazard ratios for OS across ABO blood group pairwise comparisons. Summary hazard ratios (SHRs) were estimated using random-effects models. Heterogeneity was assessed via the

                      I

                      2

                      index. Study quality and publication bias were evaluated. Twenty-three studies were included, covering over 24 000 patients. For esophageal cancer, blood group A was associated with significantly lower mortality compared with group O [SHR: 0.89, 95% confidence interval (CI): 0.83–0.95]. Group AB was associated with increased mortality compared with group A (SHR: 1.36, 95% CI: 1.09–1.70) and group B (SHR: 1.26, 95% CI: 1.00–1.59). Subgroup analyses revealed that blood group AB was associated with lower mortality in high-quality gastric cancer studies, and that blood group B was associated with significantly lower mortality compared with group A in colorectal cancer when excluding the single low-quality study (SHR: 0.70, 95% CI: 0.59–0.84), consistent with the subgroup analysis restricted to Asian studies (SHR: 0.64, 95% CI: 0.51–0.81). Our findings suggest that blood group A vs. O is associated with lower mortality in esophageal cancer and that blood group AB is associated with lower mortality in gastric cancer among high-quality studies. However, future studies are needed to confirm these findings.

                    

                  },

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Palomba2026,

title = {Impact of Driver Genetic Alterations on Survival in Metastatic Colorectal Cancer Patients from a Genetically Homogeneous Sardinian Population: A Real-World Study},

author = {Grazia Palomba and Luca Nuvoli and Maria Cristina Sini and Giovanni Battista Maestrale and Maria Grazia Doro and Laura Frogheri and Ivana Persico and Angelo Zinellu and Davide Adriano Santeufemia and Panagiotis Paliogiannis and Daniele Delogu and Fabrizio Scognamillo and Giuseppe Palmieri},

doi = {10.3390/cancers18111708},

issn = {2072-6694},

year  = {2026},

date = {2026-06-00},

journal = {Cancers},

volume = {18},

number = {11},

publisher = {MDPI AG},

abstract = {Background: Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. Recent therapeutic advancements have significantly improved clinical management, underscoring the importance of routine molecular profiling to guide personalised treatment strategies. This study aims to evaluate the prognostic impact of main molecular alterations—including allele frequency (AF) of RAS mutations—on survival outcomes in a real-world hospital-based cohort of patients with metastatic CRC. Methods: A total of 208 consecutive patients with a histologically confirmed diagnosis of CRC and complete clinical, molecular, and survival data were retrospectively analysed. Somatic mutations in KRAS, NRAS, BRAF, and the occurrence of microsatellite instability (MSI) were assessed using pyrosequencing and real-time PCR assays, respectively, on formalin-fixed, paraffin-embedded tumour samples. Associations between mutational status, clinicopathological parameters, and overall survival (OS) were evaluated. Results: Overall, 138 patients (66.3%) harboured at least one somatic mutation: 115 (55.3%) in KRAS, 8 (3.8%) in NRAS, and 15 (7.2%) in BRAF. MSI was detected in 17/208 (8.2%) patients. A statistically significant improvement in OS was observed in patients lacking mutations in any of the three genes—referred to as wild-type (WT) patients—with BRAF mutated cases showing the worst survival (p = 0.041). Increasing age at the time of first-line therapy for advanced disease stage was associated with a statistically significant increase in the hazard of death (p = 0.031). Conclusions: In the advanced disease stage, RAS/BRAF wild-type colorectal cancers were significantly associated with a survival advantage.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Gaeta2025,

title = {Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis},

author = {Aurora Gaeta and Luca Nuvoli and Chiara Doccioli and Saverio Caini and Maristella Saponara and Carolina Cimminiello and Claudia Cosma and Giuseppe Palmieri and Antonio Cossu and Francesco Vicini and Luca Mazzarella and Giulio Tosti and Paola Queirolo and Sara Gandini},

doi = {10.1038/s41416-025-03266-0},

issn = {1532-1827},

year  = {2026},

date = {2026-02-08},

journal = {Br J Cancer},

volume = {134},

number = {3},

pages = {359--366},

publisher = {Springer Science and Business Media LLC},

keywords = {},

pubstate = {published},

tppubtype = {article}

}